SCHEMBL23456064

SCHEMBL23456064

OC[C@H]1C[C@@H](Oc2cc(Cl)ncn2)[C@H](F)[C@@H]1O

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SLC5A1 P13866 3/20 0.33
▸ SLC5A2 P31639 3/20 0.33
▸ OGA O60502 1/20 0.30
▸ AHCY P23526 1/20 0.30
▸ ADORA2B P29275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27251068 0.89 AHCY (0.31) AHCY
SCHEMBL14719969 0.75 NAE1 (0.47) —
SCHEMBL23456058 0.74 TYMP (0.37) SLC5A1SLC5A2
SCHEMBL23456029 0.72 MEN1 (0.43) OGAAHCYADORA2B
SCHEMBL27251070 0.72 — —
SCHEMBL15024140 0.71 NAE1 (0.36) —
SCHEMBL23456077 0.70 — —
SCHEMBL5413891 0.68 MEN1 (0.40) —
SCHEMBL5413053 0.68 MEN1 (0.40) —
SCHEMBL19749333 0.67 NAE1 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12054512-B2 Sting modulator compounds, and methods of making and using TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-08-06 — — US disclosed
US-20240209017-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-27 — — US disclosed
US-11542293-B2 Sting modulator compounds, and methods of making and using TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-01-03 — — US disclosed
EP-3707151-B1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICALS CO (JP) 2022-01-05 — — EP disclosed
US-20210171565-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542293-B2 Sting modulator compounds, and methods of making and using STING1, CGAS, MAVS SLC5A1 3471/4885SLC5A2 4067/4885OGA 2382/4885
US-20240209017-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING STING1, CGAS, MAVS SLC5A1 3471/4885SLC5A2 4067/4885OGA 2382/4885
US-12054512-B2 Sting modulator compounds, and methods of making and using STING1, CGAS, MAVS SLC5A1 3471/4885SLC5A2 4067/4885OGA 2382/4885
US-20210171565-A1 STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING STING1, CGAS, MAVS SLC5A1 3471/4885SLC5A2 4067/4885OGA 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback